In 2022, a novel specific cell surface expression pattern in RCC represented by the NCI-60 tumor cell panel was identified and confirmed that VCAM1 is a promising novel immunotherapeutic target for the treatment of renal cancer particularly (39). Here, VCAM1 is linked to renal cell carcinoma.